OncoMatch/Clinical Trials/NCT05430009
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
Is NCT05430009 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Pembrolizumab for liver metastases.
Treatment: Pembrolizumab — Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function per protocol.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Veterans Affairs Ann Arbor Healthcare System · Ann Arbor, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05430009 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages